CRL On Other Exchanges
Symbol
Exchange
New York
Berlin

charles river laboratories (CRL) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHARLES RIVER LABORATORIES (CRL)
\

charles river laboratories (CRL) Related Bloomberg News

View More Bloomberg News

charles river laboratories (CRL) Related Businessweek News

No Related Businessweek News Found

charles river laboratories (CRL) Details

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company serves biopharmaceutical companies; biotechnology, agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic, and consumer product companies; contract research and contract manufacturing organizations; other commercial entities; and hospitals, academic institutions, and government agencies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

14,700 Employees
Last Reported Date: 02/13/19
Founded in 1947

charles river laboratories (CRL) Top Compensated Officers

Chairman, CEO & President
Total Annual Compensation: $4.5M
Corporate Executive VP & CFO
Total Annual Compensation: $1.4M
Chief Commercial Officer & Corporate Executiv...
Total Annual Compensation: $1.0M
Corporate Executive Vice President of Discove...
Total Annual Compensation: $957.4K
Corporate Executive VP, Human Resources, Gene...
Total Annual Compensation: $1.9M
Compensation as of Fiscal Year 2018.
charles river laboratories
Charles River Laboratories International, Inc. Presents at Jefferies 2019 Healthcare Conference, Jun-05-2019 08:30 AM

Charles River Laboratories International, Inc. Presents at Jefferies 2019 Healthcare Conference, Jun-05-2019 08:30 AM. Venue: Grand Hyatt, 109 E 42nd St, New York, New York, United States.

Charles River Laboratories International, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-14-2019 11:20 AM

Charles River Laboratories International, Inc. Presents at Bank of America Merrill Lynch 2019 Healthcare Conference, May-14-2019 11:20 AM. Venue: Encore Hotel, Wynn, Las Vegas, Nevada, United States. Speakers: Birgit Girshick, Executive Vice President, Discovery & Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services, David Ross Smith, Corporate Executive VP & CFO.

Charles River Laboratories International, Inc. Reaffirms Earnings Guidance for 2019

Charles River Laboratories International, Inc. announced that the company reaffirmed earnings guidance for 2019. The company expects revenue growth of 16% to 18%. GAAP earnings per share is expected to be $4.75 to $4.90.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CRL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CRL.
View Industry Companies
 

Industry Analysis

CRL

Industry Average

Valuation CRL Industry Range
Price/Earnings 28.0x
Price/Sales 2.6x
Price/Book 4.5x
Price/Cash Flow 20.8x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CHARLES RIVER LABORATORIES, please visit www.criver.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.